ANN Annual Meeting 3 September 2019

Kids Neuroscience in partnership with the Australasian Neuromuscular Network invites you to the annual ANN meeting. This year promises an impressive program with updates in genomics, clinical care and diagnostics. This meeting brings together clinicians, allied health, scientists and students in the neuromuscular field, enhancing collaborative research and shared expertise. Program highlights include international and national […]

Read full story Comments are closed

Recruitment request: SMA patient and family study

The Centre for Community-Driven Research (CCDR*) are partnering with SMA and MD organisations in Australia to conduct a study to understand the experience of those affected by SMA and their needs in relation to future treatment, support, care and information. This study will result in a report that we can all use for future advocacy […]

Read full story Comments are closed

Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases

This study demonstrates the cost-effectiveness of investigation using massively parallel sequencing technologies in paediatric muscle disease. The findings emphasise the value of implementing these technologies in clinical practice, with particular application for diagnosis of Mendelian diseases, and provide evidence crucial for government subsidy and equitable access. Please click for the full paper  

Read full story Comments are closed

CMTPedS calculator now online!

Professor Joshua Burns and the Centre of Research Excellence in Neuromuscular Disorders have just finalised a new calculation tool to measure the level of disability in children with Charcot-Marie-Tooth disease (CMT). The CMTPedS Calculator is a user-friendly online tool developed to support the CMT Pediatric Scale, which collects validated measures of strength, dexterity, sensation, gait, […]

Read full story Comments are closed

Lifeline for Pompe disease patients

RCH clinicians have worked with the Australian Pompe Association, drug company Genzyme and the Federal government to achieve government-subsidised treatment for late-onset Pompe disease. 12-year-old patient Christian Rivera received his first infusion at the RCH last week. The federal government has listed the only registered treatment for Pompe disease, Myozyme (alglucosidase alfa), on the Life […]

Read full story Comments are closed

UCL Clinical Research Associates

UCL Institutes of Neurology and Child Health MRC Centre for Neuromuscular Diseases  CLINICAL RESEARCH ASSOCIATES X 3 An exciting opportunity for three Clinical Research Associates has arisen at the MRC Centre for Neuromuscular Diseases, UCL Institutes of Neurology and Child Health. The CRAs will have the opportunity to undertake experimental and/or clinical research in neuromuscular […]

Read full story Comments are closed

New Cardiac DMD Registry

Sudden Cardiac Death in Duchenne Muscular Dystrophy: Incidence and Prevention Patient Registry Please click the below link for more information: Approved_DMD Patient Registry Flier_v2 (2)

Read full story Comments are closed

Duchenne Foundation’s Melbourne Symposium 2014

The Duchenne Foundation’s Melbourne Symposium was held on the 29th March in Melbourne, coinciding with the ANN Annual Meeting. Audio files of the Symposium’s presentations may be of interest to ANN Members and can be accessed on the Duchenne Foundation website via the link: http://goo.gl/50JB0r    

Read full story Comments are closed

Study of early signs of breathing problems during sleep in DMD

Currently there are no accurate predictors of the need for a sleep study in children with DMD. Symptoms of breathing problems in DMD are slow to develop, and often are not noticed by the individual. Once symptoms of waking with a headache or being sleep during the day are reported, a sleep study often finds […]

Read full story Comments are closed

Early Access Program for Nusinersen

Early Access Program for Nusinersen   There has been a lot of activity in the clinical trial space for the treatment of Spinal Muscular Atrophy (SMA) over the last two years, and Nusinersen, has been identified as the first effective drug to treat SMA Type 1.   Developed in California, Nusinersen (know in the USA […]

Read full story Comments are closed